Predictive Oncology Announces Collaboration with Integra Therapeutics to Advance Gene Therapy
Predictive Oncology , a science-driven company on the leading edge of oncology drug discovery and development, announces it is partnering with Integra Therapeutics, a company focused on engineering the next generation of gene writing tools to cure diseases.
Artificial Intelligence Insights: How Artificial Intelligence is Transforming Customer Service – 7 Use Cases
The collaboration was created to pursue a novel method to enhance Integra Therapeutics’ ability to use gene editing for future cancer therapies.
“Our novel formulation technology and protein expression experience positions Predictive Oncology to help advance Integra’s goals,” said Larry DeLucas, Senior Vice President of Biologics, Predictive Oncology.
Read More about Generative AI : Announcing GitHub CoPilotX: World’s Most Powerful Generative AI Pair Programming Tool
Integra Therapeutics selected Predictive Oncology because of the company’s protein expression experience and unique ability to optimize solubility and physical stability for expressed proteins. Predictive Oncology uses a proprietary automated technology, called high-throughput self-interaction chromatography (HSC™), to rapidly and accurately measure biomolecular interactions that assist pharmaceutical and biotech companies in drug development.
“This collaboration could set the stage for new discoveries in cell therapy. We are excited about the potential that Predictive Oncology offers in advancing our goals in advanced therapies,” Avencia Sanchez-Mejias, Chief Executive Officer, Integra Therapeutics.
This news comes on the heels of Predictive Oncology’s release of a novel product designed for endotoxin removal and which involves a new high-capacity endotoxin column called EndoBind-R II. This highly specialized process and unique product design continually demonstrates superior performance and consistently delivers conclusive results.
Latest AI Insights : OpenAI Announces Initial support for ChatGPT Plugins
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.